An innate immune checkpoint in cancer immunotherapy

癌症免疫治疗中的先天免疫检查点

基本信息

  • 批准号:
    9447148
  • 负责人:
  • 金额:
    $ 46.82万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-03-01 至 2022-02-28
  • 项目状态:
    已结题

项目摘要

Cancer immunotherapy attempts to boost the body’s own defense mechanism – the immune system – to kill cancer cells and defeat cancer. Immunotherapy with T cell checkpoint inhibitors is promising to revolutionize cancer therapy. However, a major limitation of these therapies is that they are effective in only a subset of patients. Recent evidence suggests that enhanced T cell infiltration in the tumor is a predictive marker of positive response to T cell checkpoint inhibitors. Thus, failure to respond to T cell checkpoint inhibitors may correspond to a defect in the ability of the innate immune system to effectively engage adaptive anti-tumor immune response. In mice, we have identified and disabled a novel immune checkpoint mechanism, a cellular protein named MERTK, that is found in innate immune cells – the body’s first line of immune defense. MERTK limits the extent to which innate immune cells can get activated, which in turn controls how much the overall immune response would be. We have also detected the presence of MERTK in tumor-associated innate immune cells in human samples. In mouse models of cancer, genetic ablation of Mertk results in dramatic prevention of cancer growth. We propose to (i) use mouse models of cancers to investigate the mechanism/s by which loss of MERTK function improves anti-tumor immunity, (ii) test if acute ablation of Mertk in established tumors and the inactivation of its kinase activity are sufficient to overcome the failure to trigger anti- tumor T cell responses and restrict tumor growth, and (iii) to investigate the association between MERTK activation and the resistance to T cell checkpoint inhibitors in patients. Through these studies, we will better understand how the immune system can fight cancer when the MERTK brake is removed, obtain proof-of- concept for therapeutic use of drugs that would inhibit MERTK, and develop a predictive biomarker panel for the identification of a subset of patients that are likely to respond to MERTK inhibitors. In summary, our proposed studies can potentially identify a novel target for cancer immunotherapy that by itself, or in combination with FDA-approved checkpoint inhibitors or molecular targeted therapies, could significantly increase the percentage of patients that show objective response to anti-cancer therapy.
癌症免疫疗法试图增强人体自身的防御机制——免疫系统——以杀死癌细胞 癌细胞并战胜癌症。 T 细胞检查点抑制剂的免疫疗法有望带来革命性变革 癌症治疗。然而,这些疗法的一个主要限制是它们仅对一小部分有效。 患者。最近的证据表明,肿瘤中 T 细胞浸润增强是以下疾病的预测标志: 对 T 细胞检查点抑制剂呈阳性反应。因此,对 T 细胞检查点抑制剂没有反应可能 对应于先天免疫系统有效参与适应性抗肿瘤能力的缺陷 免疫反应。在小鼠中,我们发现并禁用了一种新的免疫检查点机制,即细胞 名为 MERTK 的蛋白质,存在于先天免疫细胞中——人体的第一道免疫防御线。梅特克 限制了先天免疫细胞被激活的程度,进而控制了整体免疫细胞的激活程度。 免疫反应会是。我们还在肿瘤相关的先天性中检测到了 MERTK 的存在。 人体样本中的免疫细胞。在小鼠癌症模型中,Mertk 的基因消除会导致显着的结果 预防癌症生长。我们建议 (i) 使用癌症小鼠模型来研究其机制 MERTK 功能的丧失可提高抗肿瘤免疫力,(ii) 测试 Mertk 的急性消融是否在 已形成的肿瘤及其激酶活性的失活足以克服无法触发抗- 肿瘤 T 细胞反应并限制肿瘤生长,以及 (iii) 研究 MERTK 之间的关联 激活和患者对 T 细胞检查点抑制剂的耐药性。通过这些研究,我们将更好 了解当 MERTK 制动器被移除时,免疫系统如何对抗癌症,获得证据- 抑制 MERTK 的药物治疗用途的概念,并开发预测性生物标志物组 识别可能对 MERTK 抑制剂有反应的患者子集。综上所述,我们的 拟议的研究可能会确定癌症免疫疗法的新靶标,该靶标本身或在 与 FDA 批准的检查点抑制剂或分子靶向治疗相结合,可以显着 增加对抗癌治疗表现出客观反应的患者百分比。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Sourav Ghosh其他文献

Sourav Ghosh的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Sourav Ghosh', 18)}}的其他基金

Augmenting AXL and MERTK function to restrain cognitive decline and improve health span in mouse models of Alzheimer's Disease
增强 AXL 和 MERTK 功能以抑制阿尔茨海默氏病小鼠模型的认知衰退并改善健康寿命
  • 批准号:
    10662677
  • 财政年份:
    2023
  • 资助金额:
    $ 46.82万
  • 项目类别:
Naïve T cell archetypes and anti-tumor immunity
幼稚 T 细胞原型和抗肿瘤免疫
  • 批准号:
    10741153
  • 财政年份:
    2023
  • 资助金额:
    $ 46.82万
  • 项目类别:
Sex-Specific Single Cell Expression Profiles, Genetic Risk and Drug Responsiveness in Alzheimer's Disease
阿尔茨海默病的性别特异性单细胞表达谱、遗传风险和药物反应
  • 批准号:
    10467589
  • 财政年份:
    2021
  • 资助金额:
    $ 46.82万
  • 项目类别:
An innate immune checkpoint in cancer immunotherapy
癌症免疫治疗中的先天免疫检查点
  • 批准号:
    10286793
  • 财政年份:
    2017
  • 资助金额:
    $ 46.82万
  • 项目类别:
Apical-basal polarity signaling in glioblastoma
胶质母细胞瘤中的顶端-基底极性信号传导
  • 批准号:
    8657870
  • 财政年份:
    2010
  • 资助金额:
    $ 46.82万
  • 项目类别:
Apical-basal polarity signaling in glioblastoma
胶质母细胞瘤中的顶端-基底极性信号传导
  • 批准号:
    8461275
  • 财政年份:
    2010
  • 资助金额:
    $ 46.82万
  • 项目类别:
Apical-basal polarity signaling in glioblastoma
胶质母细胞瘤中的顶底极性信号传导
  • 批准号:
    8817344
  • 财政年份:
    2010
  • 资助金额:
    $ 46.82万
  • 项目类别:
Apical-basal polarity signaling in glioblastoma
胶质母细胞瘤中的顶底极性信号传导
  • 批准号:
    8915298
  • 财政年份:
    2010
  • 资助金额:
    $ 46.82万
  • 项目类别:
Apical-basal polarity signaling in glioblastoma
胶质母细胞瘤中的顶端-基底极性信号传导
  • 批准号:
    8649817
  • 财政年份:
    2010
  • 资助金额:
    $ 46.82万
  • 项目类别:
Apical-basal polarity signaling in glioblastoma
胶质母细胞瘤中的顶端-基底极性信号传导
  • 批准号:
    8527897
  • 财政年份:
    2010
  • 资助金额:
    $ 46.82万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 46.82万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 46.82万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 46.82万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 46.82万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 46.82万
  • 项目类别:
    Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 46.82万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 46.82万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 46.82万
  • 项目类别:
    Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 46.82万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
  • 批准号:
    2244994
  • 财政年份:
    2023
  • 资助金额:
    $ 46.82万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了